MX2015006249A - Ester nitrico de saquinavir para inmunomodulacion. - Google Patents

Ester nitrico de saquinavir para inmunomodulacion.

Info

Publication number
MX2015006249A
MX2015006249A MX2015006249A MX2015006249A MX2015006249A MX 2015006249 A MX2015006249 A MX 2015006249A MX 2015006249 A MX2015006249 A MX 2015006249A MX 2015006249 A MX2015006249 A MX 2015006249A MX 2015006249 A MX2015006249 A MX 2015006249A
Authority
MX
Mexico
Prior art keywords
diseases
syndrome
saquinavir
disease
autoimmune
Prior art date
Application number
MX2015006249A
Other languages
English (en)
Inventor
Ferdinando Nicoletti
Original Assignee
Onconox Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconox Aps filed Critical Onconox Aps
Publication of MX2015006249A publication Critical patent/MX2015006249A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Éster nítrico de Saquinavír o sus sales, solvatos o formas cristalinas/polimórficas no tóxicas, útiles en el tratamiento de enfermedades autoinmunes, en particular en enfermedades mediadas por medio de citocinas pro-inflamatorias; ejemplos de enfermedades que pueden ser tratadas incluyen la enfermedad de Addison idiopática, hepatitis autoinmune, cirrosis biliar, colangitis esclerosante primaria, síndrome de Guillain Barré, tiroiditis de Hashimoto, psoriasis, artritis reumatoide, síndrome de Sjogren, lupus sistémico eritomatoso, diabetes mellitus de Tipo 1 y uevítis, reperfusión isquémica, enfermedades de injerto contra huésped, rechazo de injerto, endo- y exo10 toxemia y artritis gotosa.
MX2015006249A 2012-11-20 2013-11-20 Ester nitrico de saquinavir para inmunomodulacion. MX2015006249A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728330P 2012-11-20 2012-11-20
PCT/EP2013/074264 WO2014079868A1 (en) 2012-11-20 2013-11-20 Saquinavir-no for immunomodulation

Publications (1)

Publication Number Publication Date
MX2015006249A true MX2015006249A (es) 2015-12-03

Family

ID=49759262

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006249A MX2015006249A (es) 2012-11-20 2013-11-20 Ester nitrico de saquinavir para inmunomodulacion.

Country Status (12)

Country Link
US (1) US20150283127A1 (es)
EP (1) EP2922545B1 (es)
JP (1) JP6283680B2 (es)
KR (1) KR20150084862A (es)
CN (1) CN104822379B (es)
AU (1) AU2013349804A1 (es)
BR (1) BR112015011299A2 (es)
CA (1) CA2891771A1 (es)
HK (1) HK1212895A1 (es)
IL (1) IL238866A0 (es)
MX (1) MX2015006249A (es)
WO (1) WO2014079868A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104127858A (zh) * 2014-07-26 2014-11-05 滨州医学院 甲磺酸沙奎拉韦在制备预防或治疗内毒素血症和脓毒症的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU760870B2 (en) * 1998-06-09 2003-05-22 Unger, Martin G. Dr. Method and composition for the treatment of epidermal irritations and infections
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
AU2002346594A1 (en) * 2001-12-14 2003-06-30 Cedars-Sinai Medical Center Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
ES2509493T3 (es) * 2008-08-01 2014-10-17 Onconox Aps Propiedades antitumorales de inhibidores de proteasa modificados con NO
US20130317040A1 (en) * 2010-12-22 2013-11-28 The Feinstein Institute Of Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors

Also Published As

Publication number Publication date
IL238866A0 (en) 2015-06-30
US20150283127A1 (en) 2015-10-08
CN104822379B (zh) 2017-08-25
CA2891771A1 (en) 2014-05-30
JP6283680B2 (ja) 2018-02-21
WO2014079868A1 (en) 2014-05-30
JP2015537023A (ja) 2015-12-24
EP2922545A1 (en) 2015-09-30
KR20150084862A (ko) 2015-07-22
AU2013349804A1 (en) 2015-06-04
HK1212895A1 (zh) 2016-06-24
EP2922545B1 (en) 2016-09-21
CN104822379A (zh) 2015-08-05
BR112015011299A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
PH12020550760A1 (en) Compositions and methods of use of phorbol esters
PH12018500533A1 (en) Pyrazolyl-substituted heteroaryls and their use as medicaments
EP3140403A4 (en) Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system
SI3230298T1 (sl) Spojine 3-substituiranega 5-amino-6H-tiazolo(4,5-d)pirimidin-2,7-diona za zdravljenje ali preprečevanje okužbe z virusom
IN2014MN02658A (es)
IN2014MN02657A (es)
IN2014MN02652A (es)
MD4521C1 (ro) Compuşi antivirali pe bază de imidazolil-dihidroizocromeno-naftoimidazoli condensaţi
EP2576540A4 (en) HETEROARYLATED COMPOUNDS AND METHODS OF USE
EP2773342A4 (en) COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES
EP3268086A4 (en) Lsd for the treatment of alzheimer's disease
MY183974A (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
PH12016501864A1 (en) Chromene and 1, 1a, 2, 7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
MY162397A (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
WO2013056684A3 (zh) 作为dhodh抑制剂的噻唑衍生物及其应用
EP3377116A4 (en) COMPOSITIONS AND METHODS FOR CORRECTING HEREDITARY OCULAR DISEASE
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
IL206277A0 (en) 1,2,4-oxadiazole compounds for the treatment of autoimmune diseases
NZ620074A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
EP2678009A4 (en) CYSTAMINE ANALOGS FOR THE TREATMENT OF PARKINSON'S DISEASE
MX2015006249A (es) Ester nitrico de saquinavir para inmunomodulacion.
SI3413870T1 (sl) Igmezin za uporabo pri zdravljenju alzheimerjeve bolezni
NZ728660A (en) A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor
JP2016504343A5 (es)